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Hemophilia: Definition 
• Hemophilia is an X-linked recessive hemorrhagic 
disease due to mutations in the F8 gene (factor 
VIII- FVIII) (hemophilia A or classic hemophilia) or 
F9 gene (factor IX –FIX) (hemophilia B) 
• The disease affects 1 in 1 0000 males worldwide, 
in all ethnic groups; hemophilia A represents 80% 
of all cases 
• Male subjects are clinically affected; women， 
who carry a single mutated gene, are generally 
asymptomatic 
2015-Harrison-s Principles of Internal Medicine-19th Edition 
Hemophilia: Etiology 
Hemophilia - Royal disease 
http://www.cuckari.cz/view.php?cisloclanku=2008090004 
You may have heard 
hemophilia being referred 
to as a “royal disease”. 
This is because Queen 
Victoria, who was the 
monarch of the UK in the 
1800s, was a carrier of the 
disorder. She passed the 
condition on her son 
Leopold. Several of her 
daughters were also 
carriers and they passed 
on the faulty gene to other 
royal families in Spain, 
Germany and Russia 
Hemophilia C (deficiency of factor XI) was described first in two sisters and a maternal uncle 
of an American Jewish family. Unlike the bleeding tendency in hemophilia A or hemophilia B,  
even in severe deficiency of factor XI, the bleeding tendency is mild. Some patients with 
severe deficiency do not have a bleeding tendency, whereas some patients with mild 
deficiency bleed excessively. Complications of factor XI deficiency commonly involve the 
unpredictable nature of bleeding. 
Hemophilia B, or Christmas disease, is an inherited, X-linked, recessive disorder that results 
in deficiency of functional plasma coagulation factor IX. Hemophilia B constitutes about 20% 
of hemophilia cases, and about 50% of these cases have factor IX levels greater than 1%. The 
hallmark of hemophilia is hemorrhage into the joints, resulting in permanent deformities, 
misalignment, loss of mobility, and extremities of unequal lengths.  
Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma 
clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. 
Depending on the level of FVIII activity, patients with hemophilia may present with easy 
bruising; inadequate clotting of traumatic or even mild injury; or, in the case of severe 
hemophilia, spontaneous hemorrhage.  
Acquired hemophilia is a rare but potentially life-threatening bleeding disorder caused by 
the development of autoantibodies (inhibitors) directed against plasma coagulation factors, 
most frequently factor VIII (FVIII). 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629762/ 
Classification 
Hemophilia: Pathophysiology 1.2. 
 
2015-Harrison-s Principles of Internal Medicine-19th Edition 
Type B 
Type A 
Type C 
Hemophilia: Pathophysiology 2.2. 
https://www.youtube.com/watch?v=nkC1vZaUpxs 
Hemophilia: Sings and Symptoms 1.2. 
• Ecchymoses 
• Joint pain 
• Joint swelling and redness 
• Decreased range of motion 
• Muscle hemorrage 
• Sings of nerve compression 
• Oral bleeding 
• Haematuria 
• Intracranial hemorrhage 
• Excessive postsurgical bleeding 
https://www.uspharmacist.com/article/hemophilia-review 
Hemophilia: Sings and Symptoms 2.2. 
Ecchymosis 
 
https://www.google.com.ua/search?biw=1440&bih=745&tbm=isch&sa=1&ei=TzFOW9WuLYe3sQGa-
a6QAQ&q=ecchymosis&oq=ecchymosis&gs_l=img.3..35i39k1l2j0i30k1l8.185095.186880.0.187312.11.11.0.0.0.0.139.1258.0j11.11.0....0...1c.1.64.img..0.10.1116...0i5i30k1j0i8i30k1j0i19k1j0i30i19k1j0i5i30i19k1j0i
8i30i19k1.0.ul4E3qSt1qw#imgrc=6LqreVIAO-grKM: 
Joint bleeds 
Hemophilia: Diagnosis 1.2. 
Accurate diagnosis is important and essential for 
effective management. Hemophilia should be 
suspected in patients presenting with a history 
of:  
• Easy bruising in early childhood 
• Spontaneous bleeding (particularly into the 
joints and soft tissue) 
• Excessive bleeding following trauma or surgery 
http://illinoisaap.org/wp-content/uploads/guidelines-Hemophilia-WHF-2005.pdf 
Hemophilia: Diagnosis 2.2. 
• While the history of bleeding is usually lifelong, some 
severe hemophilic children may not have bleeding 
symptoms until after the age of one or later when they 
begin walking and exploring their world. Patients with 
mild hemophilia may not have excessive bleeding 
unless they experience trauma or surgery 
 
• A family history of bleeding is commonly obtained 
 
• However, both FVIII and FIX genes are prone to new 
mutations, and as many as 1/3 of all patients may not 
have a family history of these disorders 
http://illinoisaap.org/wp-content/uploads/guidelines-Hemophilia-WHF-2005.pdf 
Hemophilia: Laboratory diagnosis 1.3. 
• Using screening tests to identify the potential 
cause of bleeding: platelet count, bleeding 
time (BT), prothrombin time (PT), activated 
partial thromboplastin time (APTT) 
• These screening tests may not detect 
abnormalities in patients with mild bleeding 
disorders and in those with factor XIII (FXIII) 
deficiency or those with low fibrinolytic 
inhibitor activity (alpha 2 antiplasmin, PAI-1) 
 
http://illinoisaap.org/wp-content/uploads/guidelines-Hemophilia-WHF-2005.pdf 
Hemophilia: Laboratory diagnosis 2.3. 
Possible 
condition 
PT APTT BT Platelet count 
Normal Normal Normal Normal Normal 
Hemophilia A 
or B 
Normal Prolonged Normal Normal 
vWD 
(Von Willebrand 
disease) 
Normal Normal or 
prolonged 
Normal or 
prolonged 
Normal or 
reduced 
Platelet defect Normal Normal 
 
Normal or 
prolonged 
Normal or 
reduced 
http://illinoisaap.org/wp-content/uploads/guidelines-Hemophilia-WHF-2005.pdf 
bleeding time (BT), prothrombin time (PT), activated partial thromboplastin time (APTT) 
 
Hemophilia: Laboratory diagnosis 3.3. 
http://illinoisaap.org/wp-content/uploads/guidelines-Hemophilia-WHF-2005.pdf 
Factor assay is required in the following situations:  
• To determine diagnosis  
• To monitor treatment  
 - The laboratory monitoring of clotting factor 
concentrates is possible by performing pre- and 
post-infusion clotting factor levels 
 - The actual amount of infused clotting factor 
given to the patient should predict the rise in blood 
levels. This approach is especially important when 
surgical procedures are to be performed 
 - Lower than expected recovery may be an 
early indicator of the presence of inhibitors 
Hemophilia: 
The severity of bleeding 
manifestations 
Severity Clotting factor level % 
activity (IU/ml) 
Bleeding episodes 
Severe 1% (< 0.01) Spontaneous bleeding, 
predominantly in joints 
and muscles 
Moderate 1%-5% (0.01-0.05) Occasional spontaneous 
bleeding. Severe bleeding 
with trauma, surgery 
Mild 5%-40% (0.05-0.40) Severe bleeding with major 
trauma or surgery 
The severity of bleeding manifestations in hemophilia is generally correlated with the 
clotting factor level as shown in the following table. 
http://illinoisaap.org/wp-content/uploads/guidelines-Hemophilia-WHF-2005.pdf 
Hemophilia: Chronic complications 
• Musculoskeletal complications: 
 - Chronic hemophilic arthropathy;  
 ❍ Chronic synovitis;  
 ❍ Deforming arthropathy;  
- Contractures 
- Pseudotumour formation (soft tissue and bone); 
- Fracture; 
- Inhibitors against FVIII/FIX;  
• Transfusion-related infections of concern in people with 
hemophilia:  
- Human immunodeficiency virus (HIV);  
- Hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis A virus (HAV); 
- Parvovirus B19;  
- Others 
http://illinoisaap.org/wp-content/uploads/guidelines-Hemophilia-WHF-2005.pdf 
Hemophilia: Treatment 
History 
 The treatment of hemophiliacs has evolved significantly over the past 50 
years. Initially, the mainstay treatment modalities available for hemophilia were whole 
blood and fresh-frozen plasma. As a result of low factor VIII and IX levels in those 
products, most patients with severe hemophilia did not survive past early adulthood. 
The modern era of hemophilia management came into existence in the 1970s with the 
availability of plasma concentrates 
 Desmopressin, a synthetic medication that increases factor VIII and von 
Willebrand factor levels, provided a new, inexpensive method of safely treating 
patients with mild hemophilia A while minimizing risks of blood-borne infections. In 
the early 1980s, new challenges in the treatment of hemophilia arose as a vast 
number of patients with severe hemophilia became infected with HIV and hepatitis C 
transmitted by contaminated factor concentrates pooled from thousands of donors 
 As a result of this epidemic, the need for safer treatment of hemophilia 
developed  
 This lead to the cloning of factor VIII and IX genes, when the industrial 
production of recombinant factor VIII and factor IX became readily available. 
Additional measures have since been implemented to improve safety during the 
manufacturing process 
https://www.uspharmacist.com/article/hemophilia-review 
Hemophilia: Treatment 
The general principles of care for hemophilia 
management include the following: 
• Prevention of bleeding should be the goal 
• Acute bleeds should be treated early (within 
two hours, if possible) 
• Home therapy should be used to manage only 
uncomplicated mild/moderate bleeding 
episodes 
2015-Harrison-s Principles of Internal Medicine-19th Edition 
Hemophilia: Treatment 
The general principles of care for hemophilia management 
include the following: 
• Clotting factor concentrate replacement or DDAVP should 
be given to achieve appropriate factor levels prior to any 
invasive procedures 
• As much as possible, patients should avoid trauma by 
adjusting their lifestyle 
• Patients should be advised to avoid use of drugs that affect 
platelet function, particularly acetylsalicyclic acid (ASA) and 
non-steroidal anti-inflammatory drugs (NSAIDs), except 
certain COX-2 inhibitor 
• The use of paracetamol/acetaminophen is a safe 
alternative for analgesia 
http://illinoisaap.org/wp-content/uploads/guidelines-Hemophilia-WHF-2005.pdf 
Hemophilia: Treatment 
The general principles of care for hemophilia 
management include the following: 
• Intramuscular injections, difficult phlebotomy, 
and arterial punctures must be avoided 
• Regular exercise should be encouraged to 
promote strong muscles, protect joints, and 
improve fitness 
• Contact sports should be avoided, but swimming 
and cycling with appropriate gear should be 
encouraged 
http://illinoisaap.org/wp-content/uploads/guidelines-Hemophilia-WHF-2005.pdf 
Hemophilia: Treatment 
Adjunctive management 
• RICE (rest, ice, compression, and elevation) is an 
important adjunctive management for bleeding in 
muscles and joints in addition to increasing factor 
level with clotting factor concentrates or 
desmopressin in mild hemophilia A 
• Application of cold/ice packs is useful to decrease 
inflammation, but ice should be wrapped in a towel 
and not be applied directly to the skin 
• It is recommended that ice be applied for 20 
minutes, every four to six hours, until swelling and 
pain decrease 
http://illinoisaap.org/wp-content/uploads/guidelines-Hemophilia-WHF-2005.pdf 
Hemophilia: Treatment 
Management of bleeding 
One unit is defined as amount of FVIII (100 ng/m L) or FIX (5 μg/mL) in 
1 mL of normal plasma.  
One unit of FVIII  per kilogram of body weight increases the plasma 
FVIII  level by 2%. One can calculate the dose needed to increase of 
FVIII levels to 100% in a 70-kg severe hemophilia patient (< 1 %) using 
the simple formula below. Thus, 3500 units of FVIII will raise the 
circulating level to 100%. 
FVIII dose (IU)=Target FVIII levels- FVIII baseline levels*body weight 
(kg)*0.5 unit/kg 
 
The doses for FIX replacement are different from those for of FVIII, 
because FIX recovery after infusion is usually only 50% of the predicted 
value. Therefore, the formula for FIX replacement is as follows: 
FIX dose (IU)=Target FIX levels- FIX baseline levels*body weight 
(kg)*1  unit/kg 
2015-Harrison-s Principles of Internal Medicine-19th Edition 
Hemophilia: Treatment 
Management of bleeding 
• The FVIII half-life of 8-12 h requires 
injections twice a day to maintain 
therapeutic levels, whereas the FIX half-
life is longer-24 h, so that once-a-day 
injection is sufficient 
• Cryoprecipitate is still in use in some 
developing countries, but because of the 
risk of bloodborne diseases, this product 
should be avoided in hemophilia patients 
when factor concentrates are available 
 2015-Harrison-s Principles of Internal Medicine-19th Edition 
http://illinoisaap.org/wp-content/uploads/guidelines-Hemophilia-WHF-2005.pdf 
Pain management  
Acute and chronic pain are common in patients with hemophilia. Pain can be treated with 
local measures (eg, cold packs, immobilization, splinting), acetaminophen, or codeine 
Chronic hemophilic arthropathy develops in 
patients who have not been adequately 
treated with clotting factor concentrates for 
joint bleeding. COX-2 inhibitors have a greater 
role in this situation. Other NSAIDs should be 
avoided. When pain is disabling, orthopedic 
surgery may be indicated.  
Pain caused by joint or muscle bleeding 
While clotting factor concentrates 
should be administered as quickly as 
possible to stop bleeding, additional 
drugs are often needed for pain control. 
Other measures include cold packs, 
immobilization, splints, and crutches 
 
 
Hemophilia: Treatment 
https://www.uspharmacist.com/article/hemophilia-review 
Agents used to treat hemophilia 
Prophylaxis prevents bleeding and joint destruction and 
should be the goal of therapy to preserve normal 
musculoskeletal function 
Prophylaxis 
 
Thrombocytopenic purpura (TP): 
definition 
TP is the general term for 
purpura that accompanies 
a decrease in platelet 
density. When that 
density is less than 
100,000 per microliter, 
subcutaneous bleeding is 
easily produced by 
bruising 
When it is less than 
50,000 per microliter, 
bleeding becomes marked 
and causes purpura 
 
https://www.derm-hokudai.jp/shimizu-dermatology/pdf/11-04.pdf 
Platelets 
Platelets are released from the megakaryocyte, likely under 
the influence of flow in the capillary sinuses. The normal 
blood platelet count is 150,000 - 450,000/μL  
The major regulator of platelet productionis the hormone 
thrombopoietin (TPO), which is synthesized in the liver.  
Platelets circulate with an average life span of 7 - 10 days  
 
Approximately one - third of the platelets reside in the spleen, 
and this number increases in proportion to splenic size, 
although the platelet count rarely decreases to <40,000/μL as 
the spleen enlarges  
 
Platelets are physiologically very active, but are anucleate, 
and thus have limited capacity to synthesize new proteins 
2015-Harrison-s Principles of Internal Medicine-19th Edition 
Thrombocytopenic purpura (TP): 
classification 
TPis classified by pathogenesis into: 
• Immune thrombocytopenic purpura (also 
termed idiopathic thrombocytopenic purpura 
(ITP), which is caused by auto-antiplatelet 
antibodies 
• symptomatic thrombocytopenic purpura (STP), 
which accompanies drug-induced purpura, 
leukemia, bone-marrow cancer, SLE, infectious 
diseases  
• hereditary thrombocytopenic purpura (HTP), 
which accompanies Wiskott-Aldrich syndrome 
and Fanconi syndrome 
https://www.derm-hokudai.jp/shimizu-dermatology/pdf/11-04.pdf 
ITP: Epidemiology 
• The incidence of primary ITP in adults is 
3.3/100 000 adults per year with a prevalence 
of 9.5 per 100 000 adults 
• There is a predilection for female patients in 
younger adults, but the prevalence of ITP in 
men and women is fairly even in the elderly 
(>65 years) 
https://www.derm-hokudai.jp/shimizu-dermatology/pdf/11-04.pdf 
ITP: Pathogenesis 
• Thrombocytopenia results from pathologic 
antiplatelet antibodies, impaired 
megakaryocytopoiesis and T-cell–mediated 
destruction of platelets with each pathologic 
mechanism playing varying roles in each patient 
• Decreased platelet density (100,000 per 
microliter or less) and an extended duration of 
bleeding (3 minutes or longer) are observed. 
Platelet associated IgG (PAIgG) is found in the 
blood in more than 90% of cases 
• In a bone-marrow biopsy, the megakaryocyte 
count is found to be elevated from consumption 
of platelets 
https://www.derm-hokudai.jp/shimizu-dermatology/pdf/11-04.pdf 
http://www.bloodjournal.org/content/bloodjournal/129/21/2829.full.pdf?sso-checked=true 
ITP: Clinical picture 1.2. 
• ITP occurs in children during recovery from 
infectious disease 
• In adults it develops without any particular 
pathogenesis 
• Its main symptoms are cutaneous petechiae 
and ecchymosis, which are followed by 
bleeding in the oral mucosa, nasal mucosa 
and gingiva; hematuria; melena and 
menorrhagia 
• Splenomegaly is not found 
https://www.derm-hokudai.jp/shimizu-dermatology/pdf/11-04.pdf 
ITP: Clinical picture 2.2. 
https://www.derm-hokudai.jp/shimizu-dermatology/pdf/11-04.pdf 
Petechiae vs Purpura 
ITP: Descriptive terminology 
http://www.bloodjournal.org/content/bloodjournal/129/21/2829.full.pdf?sso-checked=true 
ITP: Laboratory testing 
• Serologic testing is usually not helpful due to the low sensitivity and 
specificity of the current tests.  Bone marrow examination can be reserved 
for those who have other signs or laboratory abnormalities not explained 
by ITP or in patients who do not respond to initial therapy 
• The peripheral blood smear may show large platelets, with otherwise 
normal morphology 
• Depending on the bleeding history, iron-deficiency anemia may be present 
• Laboratory testing is performed to evaluate for secondary causes of ITP : 
– HIV infection and hepatitis C (and  other infections if indicated) 
– serologic testing for SLE  
– serum protein electrophoresis 
– immunoglobulin levels to potentially detect hypogammaglobulinemia 
– selective testing for IgA deficiency or monoclonal gammopathies 
– testing for H. pylori infection should be considered 
• If anemia is present, direct antiglobulin testing (Coombs' test) should be 
performed to rule out combined autoimmune hemolytic anemia with ITP 
(Evans‘ syndrome) 
2015-Harrison-s Principles of Internal Medicine-19th Edition 
ITP: Treatment 1.2. 
First-line management 
• Initial treatment in patients without significant 
bleeding symptoms, severe thrombocytopenia (<5 
000/μL), or signs of impending bleeding (such as retinal 
hemorrhage or large oral mucosal hemorrhages)can be 
instituted as an outpatient using single agents 
• Prednisone 1 mg/kg/d for 2 to 4 weeks has been the 
standard first-line treatment for many years 
• However, recent work has investigated whether 
intensification of treatment, in adults with ITP, by using 
high dose dexamethasone (HDD), rituximab, or the 
TPO-RA may result in increased remission rates 
http://www.bloodjournal.org/content/bloodjournal/129/21/2829.full.pdf?sso-checked=true 
ITP: Treatment 2.2. 
Second-line therapy 
• Splenectomy has been used for treatment of patients who 
relapse after glucocorticoids are tapered 
• Splenectomy remains an important treatment option 
• However, the long-term complications of splenectomy in 
ITP patients are hemorrhage, infection, and venous 
thromboembolism (VTE) 
• The most recent clinical development that has changed 
the landscape of second-line ITP therapy is the TPO –
receptor agonists (TPO-RA) (romiplostim and eltrombopag 
are both US Food and Drug Administration approved for 
adults with chronic ITP, and eltrombopag is approved for 
use in children as well) 
http://www.bloodjournal.org/content/bloodjournal/129/21/2829.full.pdf?sso-checked=true 
STP: Thrombotic thrombocytopenic 
purpura  
• Thrombotic thrombocytopenic purpura (TTP) is 
rare, with a reported incidence of six cases per 
million per year  
• It is an important diagnosis to make because the 
untreated mortality is 90%, which can be reduced 
with the prompt delivery of plasma exchange 
• Early death still occurs: approximately half of the 
deaths occurred within 24 h of presentation, 
primarily in women  
2015-Harrison-s Principles of Internal Medicine-19th Edition 
STP: Causes 
https://www.derm-hokudai.jp/shimizu-dermatology/pdf/11-04.pdf 
STP: Thrombotic thrombocytopenic 
purpura  
• Defined by thrombocytopenia, microangiopathic 
haemolytic anaemia (MAHA) and small vessel 
thrombosis 
• Thrombotic thrombocytopenic purpura (TTP) and 
hemolytic-uremic syndrome (HUS), were previously 
considered overlap syndromes. However, in the past 
few years, the pathophysiology of inherited and 
idiopathic TTP has become better understood and 
c1early differs from HUS. 
• The pathogenesis of inherited (Upshaw-Schulman 
syndrome) and idiopathic TTP is related to a deficiency 
of, or antibodies to, the metalloprotease ADAMTS 13 
2015-Harrison-s Principles of Internal Medicine-19th Edition 
STP: Thrombotic thrombocytopenic 
purpura  
Presenting clinical features and signs in acute 
thrombotic thrombocytopenic purpura  
https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2012.09167.x 
STP: Thrombotic thrombocytopenic 
purpura  
Laboratory  tests for diagnosis 
 
https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2012.09167.x 
STP: Thrombotic thrombocytopenic 
purpura  
Laboratory  tests for diagnosis 
 
https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2012.09167.x 
STP: Thrombotic thrombocytopenic 
purpura  
Treatment 
 
• Plasma exchange remains the mainstay of treatment of TTP 
• ADAMTS 13 anti body-mediated TTP (idiopathic TTP) appears to 
respond best to plasma exchange 
• Plasma exchange is continued until the platelet count is normal 
and signs of hemolysis are resolved for at least 2 days 
• Although never evaluated in clinical trials, the use of 
glucocorticoids seems a reasonable approach, but should only 
be used as an adjunct to plasma exchange 
• Additionally, other immunomodulatory therapies have been 
reported to be successful in refractory or relapsing TIP, 
including rituximab, vincristine, cyclophosphamide,  and 
splenectomy 
https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2141.2012.09167.x 
HTP: Wiskott-Aldrich syndrome 
  
• Wiskott–Aldrich syndrome (WAS) is an X-linked 
primary immunodeficiency disorder that is 
characterized by the classic triad of severe 
immunodeficiency, microthrombocytopenia and 
eczema 
• The incidence of this rare X-linked primary 
immunodeficiency disorder is approximately one to 
four cases per 1,000,000 live male births, with an 
average age at diagnosis of 24 months in families 
without a previously affected family member 
• The estimated prevalence of WAS in the US is 1.2% of 
patients with identified primary immune defects 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012343/ 
HTP: Wiskott-Aldrich syndrome 
Symptoms  
• Thrombocytopenia and very small platelets usually 
present at birth which can result in: 
– Bleeding inside the brain, which can be very fatal 
– Mucosal bleeding 
– Bloody diarrhea 
– Purpura and petechiae 
– Life-threatening bleeding (occurs in 30% of males prior to diagnosis) 
• Red patches of red and irritated skin (eczema), occurs in about 
80% of the cases and can be mild to severe 
• Other skin diseases such as impetigo, cellulitis, and abscesses 
• Increased risk of infections, especially to recurrent bacterial and 
viral infections 
• Increased risk of developing autoimmune disorders 
• Increased risk of developing some types of cancer, such 
as lymphoma 
 
https://rarediseases.info.nih.gov/diseases/7895/wiskott-aldrich-syndrome 
HTP: Wiskott-Aldrich syndrome 
Treatment 
• The prevention of infectious complications is 
required. Intravenous Ig (IVIG) is an important 
adjunct in the treatment of WAS patients 
• For severe manifestations of autoimmunity, 
immunomodulatory therapy including IVIG may 
improve symptoms. Corticosteroids are widely 
utilized; however, the toxicity associated with the 
use of these agents is often large 
• Transplantation is the current accepted curative 
approach for patients with WAS 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4012343/ 
Case report 1.4. 
• An 85-year-old man presented with bruising of his hands, 
which he first noticed after shovelling snow 3 days earlier 
• His past medical history included benign prostatic 
hypertrophy and glaucoma 
• He was not taking anticoagulants or nonsteroidal anti-
inflammatory drugs 
• Over the last 3 days the bruising had become extensive, 
encompassing the palmar and dorsal aspect of both hands 
and spreading to the lower forearms (Figure 1) 
• The patient had no other bruising, nosebleeds, hematuria, 
bloody stools or hemoptysis, and he reported having no 
joint or muscle pains 
• He did not have a history of liver disease, nor did he have 
any personal or family history of bleeding or clotting 
disorders. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942092/ 
Case report 2.4. 
Figure 1: Hands of elderly man showing bruising on 
palmar and dorsal aspects of both hands that extended 
to forearms 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942092/ 
Case report 3.4. 
• On examination, the patient looked well and was afebrile, and his vital signs were 
stable. Aside from the extensive bruising of both hands, no other bruising, 
petechiae or sites of active bleeding were discovered, and there was no evidence 
of hemarthrosis. 
• Initial laboratory investigations revealed a normal complete blood count, with a Hb 
of 130 g/L, a platelet count of 199 × 109/L and normal electrolyte levels. Kidney 
and liver function were normal, as was the blood glucose level. The D-dimer level 
was slightly elevated, at 250–500 (normal < 250) ng/mL. 
• The prothrombin time and international normalized ratio were normal; the 
activated partial thromboplastin time was elevated, at 117 (normal < 35) seconds. 
A 1:1 mixing assay initially showed a corrected activated partial thromboplastin 
time of 41 seconds; however, a time-delayed 1:1 mix could not correct the 
thromboplastin time, which suggested that clotting factor inhibitors were present 
in the patient's blood 
• Because only the activated partial thromboplastin time was affected, we assayed 
for clotting factors specific to the intrinsic pathway and determined that the 
patient had a factor VIII deficiency (titre < 0.01 [normal 0.5–1.5] U/mL) 
• Further assays revealed factor VIII inhibitors in the patient's serum, at a level of 
12.0 (normal 0) Bethesda units 
• Acquired hemophilia was diagnosed 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942092/ 
Case report 4.4. 
• The patient was admitted to hospital and given oral prednisone therapy 
(60 mg/d). Because no sites of active bleeding were identified, no 
additional treatment was initiated. His activated partial thromboplastin 
time gradually improved, and no further bleeding or bruising occurred. 
He was discharged home 4 days later and given a tapered course of 
prednisone. 
• One month after the patient completed the course of prednisone, his 
activated partial thromboplastin time was again prolonged. He required 
a combined course of cyclophosphamide and prednisone. His condition 
is currently maintained on 50 mg of cyclophosphamide daily, with a 
normal activated partial thromboplastin time and no further bleeding. 
• Investigations into the cause of this patient's acquired hemophilia 
included chest radiograph, computed tomography of the chest and 
abdomen, and blood work to rule out malignant or autoimmune 
diseases 
• Findings were normal, and the acquired hemophilia was assumed to be 
idiopathic in nature 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1942092/ 
